Horizon Illumination Lab Optics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Early Stage VC
- Investors
-
9
Horizon Illumination Lab Optics General Information
Description
Developer of an optical diagnostic agent designed for the treatment of chronic myeloid leukemia. The company's agent visualizes the effects of molecularly targeted drugs on each living cell to measure the efficacy by introducing cancer cells to the drug agents, enabling doctors to measure the effects of other cancer therapeutics by partially changing their structure and providing optimal treatment for each patient.
Contact Information
Website
www.horizonillumination.co.jpCorporate Office
- 2-12 Kita 21-jo Nishi
- Kita-ku
- Sapporo, Hokkaido 001-0021
- Japan
Corporate Office
- 2-12 Kita 21-jo Nishi
- Kita-ku
- Sapporo, Hokkaido 001-0021
- Japan
Horizon Illumination Lab Optics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 29-Nov-2024 | Completed | Clinical Trials - General | |||
| 4. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 3. Seed Round | 01-Feb-2023 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 01-Nov-2022 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Horizon Illumination Lab Optics Patents
Horizon Illumination Lab Optics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4589011-A1 | Reagent for measuring tyrosine kinase activity, and use thereof | Pending | 12-Sep-2022 | ||
| US-20260092919-A1 | Reagent for measuring tyrosine kinase activity, and use thereof | Pending | 12-Sep-2022 | ||
| WO-2024058178-A1 | Reagent for measuring tyrosine kinase activity, and use thereof | Inactive | 12-Sep-2022 | C07K14/71 |
Horizon Illumination Lab Optics Signals
Horizon Illumination Lab Optics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| D2 Garage | Venture Capital | Minority | ||
| Green Core | Venture Capital | Minority | ||
| Japan Science And Technology Agency | Government | Minority | ||
| DG Ventures | Corporate Venture Capital | Minority | ||
| Hokkaido 21st Century Research Institute | Venture Capital | Minority |
Horizon Illumination Lab Optics FAQs
-
When was Horizon Illumination Lab Optics founded?
Horizon Illumination Lab Optics was founded in 2021.
-
Where is Horizon Illumination Lab Optics headquartered?
Horizon Illumination Lab Optics is headquartered in Sapporo, Japan.
-
What is the size of Horizon Illumination Lab Optics?
Horizon Illumination Lab Optics has 10 total employees.
-
What industry is Horizon Illumination Lab Optics in?
Horizon Illumination Lab Optics’s primary industry is Drug Discovery.
-
Is Horizon Illumination Lab Optics a private or public company?
Horizon Illumination Lab Optics is a Private company.
-
What is Horizon Illumination Lab Optics’s current revenue?
The current revenue for Horizon Illumination Lab Optics is .
-
Who are Horizon Illumination Lab Optics’s investors?
D2 Garage, Green Core, Japan Science And Technology Agency, DG Ventures, and Hokkaido 21st Century Research Institute are 5 of 9 investors who have invested in Horizon Illumination Lab Optics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process